Development of [18F]Maleimide-Based Glycogen Synthase Kinase-3β Ligands for Positron Emission Tomography Imaging for Positron Emission Tomography Imaging

Novel 18F-labeled GSK3β inhibitors that can cross the blood brain barrier.

Background:

Dysregulation of Glycogen Synthase Kinase 3β (GSK3β) is associated with several neurodegenerative diseases, such as Parkinson’s, Alzheimer's and Huntington's. Therefore, development of a selective GSK3β PET tracer would enable both, early detection of its aberrant activity and facilitate therapeutic drug discovery. However, efforts to develop a potent tracer has remained unsuccessful due to either poor penetration of the blood-brain-barrier (BBB) and/ or short half life of traditional radio-label conjugate, 11C, used as a radio-label.

Technology Overview:

Researchers at Stony Brook University have developed novel 18F radiolabeled GSK3β inhibitors. 18F radiolabeling offer several advantages to these inhibitors:

 

Long half life (t1/2 = 109.7m) which eliminates the reliance on in-house cyclotron thus facilitating wide spread use.

Better spatial resolution and image quality due to short range positron emission. Additionally, these compounds are highly potent (IC50 = 1.7nM) and have been demonstrated to cross BBB in rodents (Figure 1.).

Further Details:

 

Hu et al. ACS Medicinal Chemistry Letters, 8, 287-292, 2017

Advantages:

Longer t1/2 of 18F ( vs traditional 11C) labeled tracers

Demonstrated brain penetration

Improved spatial resolution and image quality

High potency

Applications:

- Medical Imaging

- Diagnostics 

- Therapeutics

 

8894

Intellectual Property Summary:

Patent application submitted

Stage of Development:

PCT application covering compositions and methods of use (PCT/US18/13446).

Licensing Potential:

Licensing Status:

Additional Information:

tracer,neurological,neurological disorder,inhibitor,brain,kinase,neurodegenerative,neurodegenerative disease,parkinson,alzheimer,huntington's,pet tracer,drug discovery,label,conjugate,radiolabeling,cyclotron,spatial resolution,image quality,medicinal chemistry,medical imaging,imaging,diagnostic,pet scan,pet imaging,positron emission tomography,positron emission tomography scan,neural,neural degeneration,neuro imaging,neurological disease,neurological diseases,neurology,neurology diagnostics,neurology therapeutic,neuroscience,neuroscience research,neurosciences,neurodegeneration,neurodegenerative disorder,neurodegenerative treatment,blood-brain barrier,bbb,parkinson's,parkinson's diagnosis,parkinson's disease,parkinson's disease diagnosis,parkinsons,alzheimer's diagnosis,alzheimer's disease,alzheimer's disease staging,alzheimer's treatment,alzheimer’s,huntington's disease,huntingtons,radioactive tracer,trace element,trace detection,radiolabel,radiolabeled tracer,radiolabelling,medical image,diagnostic imagin

https://stonybrook.technologypublisher.com/files/sites/sxmoen3syqdlibhcld3q_mstat1.png

Please note, header image is purely illustrative. Source: SciBiograph, Wikimedia Commons, CC BY-SA 4.0, edited.

Patent Information:
Technology/Start-up ID: